Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
0
Authors
Joseph Fraietta
Joseph Fraietta•Kyle Beckwith•Marcela Maus
Published
January 27, 2016
Abstract
Key Points Ibrutinib treatment of CLL enhances the generation of CAR T cells for adoptive immunotherapy. Concurrent ibrutinib therapy improves the engraftment and therapeutic efficacy of anti-CD19 CAR T cells in mouse models.
